Clarametyx Biosciences, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2020-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.clarametyx.com
A Study to Evaluate the Safety of CMTX-101 in People with Cystic Fibrosis
Phase 1
Recruiting
- Conditions
- Persistent InfectionCystic Fibrosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-12-07
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Clarametyx Biosciences, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT06159725
- Locations
- 🇺🇸
University of Alabama, Birmingham, Birmingham, Alabama, United States
🇺🇸Stanford University, Palo Alto, California, United States
🇺🇸National Jewish Health, Denver, Colorado, United States
A 2-Part First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of CMTX-101
Phase 1
Terminated
- Conditions
- Community-acquired PneumoniaBacterial Pneumonia
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-11-29
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Clarametyx Biosciences, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT05629741
- Locations
- 🇺🇸
The Ohio State University, Columbus, Ohio, United States
🇺🇸Augusta University Health, Augusta, Georgia, United States
🇺🇸Snake River Research, PLLC, Idaho Falls, Idaho, United States
© Copyright 2025. All Rights Reserved by MedPath